Weed and Adderall: What Mixing Them Actually Does

Almost every article in this series ends up being about a liver enzyme. This one is interesting because the obvious enzyme theory was actually tested in people and it did not hold up.

Amphetamine's hydroxylation depends on CYP2D6, cannabinoids inhibit a range of cytochrome P450 enzymes, and so the natural hypothesis is that cannabis raises amphetamine levels. That hypothesis has been checked. It failed.

Can You Take Adderall and Weed Together?

No study has measured the combination directly, and there is no established pharmacokinetic interaction.

What remains after the enzyme question is answered is a cardiovascular question and a behavioral one, and both are more practically important than the metabolism ever was.

Does Cannabis Inhibit CYP2D6? The Answer Is No

This is the useful negative result in this article.

In a randomized, double blind crossover trial in 18 healthy adults, cannabinoids were given orally and enzyme activity was measured with a validated probe cocktail. Dextromethorphan served as the CYP2D6 probe. The cannabidiol dominant product, which contained 640 mg cannabidiol plus 20 mg THC, had no effect on dextromethorphan exposure, peak concentration or half life. The THC dominant product produced no interaction either.

CYP2D6 came through untouched while other enzymes in the same experiment did not. Since CYP2D6 is the pathway most relevant to amphetamine hydroxylation, the most plausible route for a cannabis effect on Adderall levels is the one route that was measured and came back negative.

That is a stronger answer than this field usually offers, and it points away from a metabolic interaction.

The Enzymes That Were Affected

Two other enzymes in the same experiment did shift, and both make smaller contributions to amphetamine metabolism.

The cannabidiol dominant product increased caffeine exposure, a CYP1A2 probe, by 32 to 39 percent. It increased midazolam exposure, a CYP3A probe, by 56 percent with peak concentration up 28 percent.

Amphetamine metabolism involves both CYP1A2 and CYP3A4 as secondary contributors. So a modest effect cannot be excluded on the evidence, only the large CYP2D6 mediated one that would have been the main concern. Nobody has measured amphetamine itself.

The Route Contradiction Nobody Talks About

Here is the part that is genuinely speculative and worth flagging as such, because it points in two directions at once.

Oral cannabidiol inhibits CYP1A2, as the caffeine result above shows. But cannabis smoke does the opposite: combustion products induce CYP1A2, the same mechanism by which tobacco smoke does, and the induction from the two is additive.

Inhibition slows clearance of CYP1A2 substrates. Induction speeds it. So for the minor CYP1A2 contribution to amphetamine metabolism, a high cannabidiol edible and a smoked joint would be expected to push in opposite directions.

No study has tested whether this produces any measurable difference in amphetamine levels, and given that CYP1A2 is a secondary pathway the effect may well be too small to matter. It is included because it is a real and rarely mentioned asymmetry, and because it means "cannabis" is not one exposure for this purpose. Treat it as a hypothesis, not a finding.

The Cardiovascular Question

This is the concern that survives the enzyme analysis, and it does not depend on metabolism at all.

Amphetamine raises heart rate and blood pressure. That is a direct pharmacological effect and it is why the drug carries cardiovascular warnings. Cannabis acutely raises heart rate, which the does weed raise blood pressure post covers in more detail.

Nobody has measured the two together. Expecting the cardiovascular effects to add rather than cancel is the reasonable default, and that expectation matters most for anyone with an existing heart condition, high blood pressure, or a family history of cardiac events. It matters least for a healthy young adult, which is not the same as not mattering.

A note on precision: the Adderall labeling warns that amphetamine may potentiate the cardiovascular effects of sympathomimetic agents. Cannabis is not a sympathomimetic, so that specific labeled warning does not cover it. The additive expectation stated here rests on each drug's own known effect on heart rate, not on that label statement.

A Stimulant and a Depressant at the Same Time

The least chemical and most practical risk in this article.

Each drug can mask the other. A stimulant blunts the sedation that would otherwise tell you how much cannabis you have taken. Cannabis can take the edge off overstimulation that would otherwise tell you the stimulant dose is too high. The internal signals people use to self regulate become unreliable in both directions.

The consequences are the ordinary ones. Taking more than intended. Misjudging fitness to drive. Compounding anxiety, since both stimulants and higher THC doses can produce it and neither reliably cancels the other.

What About Cannabis and ADHD?

Deliberately out of scope.

Whether cannabis helps, hurts or does nothing for ADHD symptoms is a separate question with its own evidence base, and it is not addressed here. Nothing in this article should be read as suggesting cannabis is a treatment for ADHD or a replacement for prescribed stimulant medication.

The eligibility point is narrower and can be stated cleanly: ADHD is not among the listed qualifying conditions in the Florida, Georgia or Texas programs. A stimulant prescription on your medication list does not by itself affect whether you qualify under some other condition.

What Should You Tell Your Physician?

Say that you take a prescribed stimulant, and name the dose. Say whether you have any cardiovascular history or elevated blood pressure, because that is the factor that turns this from a low priority mention into a real consideration.

Mention the route you use, given the CYP1A2 asymmetry above, and the cannabidiol content if you use a high cannabidiol product.

What This Means for Florida, Georgia, and Texas Patients

A stimulant prescription is not a barrier to certification in any of the three programs, and Miracle Leaf® physicians review the full medication list as part of the evaluation. Eligibility rests on the qualifying condition, not on what else is on the list.

Program details are on the Florida marijuana laws, Georgia marijuana laws, and Texas marijuana laws pages, certification is covered on the Florida, Georgia, and Texas pages, and the full condition list per state is on the qualifying conditions page.

What If You Live Outside Florida, Georgia, and Texas?

Miracle Leaf® operates clinics in Florida, Georgia, and Texas and offers telehealth evaluations in additional states. The telehealth page covers which states are served, and the states where cannabis is legal post covers the national picture.

Sources for Cannabis and Amphetamine

• Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Bansal S, et al. Clin Pharmacol Ther. 2023;114(3):693 to 703. doi:10.1002/cpt.2973. PMCID PMC11059946. Source of the crossover design, the null CYP2D6 result using dextromethorphan, the caffeine increase of 32 to 39 percent for CYP1A2, and the midazolam increases of 56 percent and 28 percent for CYP3A.
• ADDERALL prescribing information. FDA structured product label, DailyMed. Source of amphetamine's pH dependent urinary excretion, the CYP2D6 involvement in hydroxyamphetamine metabolism, and the sympathomimetic potentiation statement discussed above.
• Dextroamphetamine-Amphetamine. StatPearls, NCBI Bookshelf. Source of the CYP1A2 and CYP3A4 contributions to amphetamine metabolism and of the CYP2D6 polymorphism context.
• Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Source of cannabis smoke inducing CYP1A2 through the same aromatic hydrocarbon mechanism as tobacco, and of the induction being additive between the two.

Related Health and Eligibility Resources

• The does weed raise blood pressure post covers the cardiovascular effects that carry most of the risk in this combination.
• The cannabis and antidepressants post covers the other psychiatric medication question in this series.
• The cannabis and Xanax post covers the depressant side of the same medication list.
• The qualifying conditions page covers eligibility across all three state programs.

Talk to a Physician About Your Medication List

Bring the stimulant and its dose, and any cardiovascular history. That second item is what changes the recommendation.

Call (833) LEGAL-MJ or contact us online to book. Evaluation pricing is on the pricing page, and the clinicians who review this content are listed on the editorial team page.

Disclaimer

This post is informational and is not medical advice. No published study has measured cannabis with amphetamine. The enzyme results cited were obtained with probe drugs, dextromethorphan, caffeine and midazolam, in healthy volunteers given oral cannabinoids, and they describe those probes rather than amphetamine. The null CYP2D6 result reduces the likelihood of a large metabolic interaction; it does not exclude a smaller one through CYP1A2 or CYP3A4, which have not been tested with amphetamine. The route dependent CYP1A2 asymmetry described above is a hypothesis drawn from separate lines of evidence and has not been tested for this drug pair. The additive cardiovascular expectation is an inference from each drug's known effects, not a measurement, and is not supported by the labeled sympathomimetic warning, which does not cover cannabis. This article does not evaluate cannabis for ADHD. Do not start, stop or change a prescribed stimulant based on this article. Discuss cannabis use with the physician who prescribes it.